Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity by unknown
Du et al. J Transl Med  (2016) 14:276 
DOI 10.1186/s12967-016-1032-4
RESEARCH
Leptin decreases the expression 
of low-density lipoprotein receptor via PCSK9 
pathway: linking dyslipidemia with obesity
Ying Du†, Sha Li†, Chuan‑Jue Cui, Yan Zhang, Sheng‑Hua Yang and Jian‑Jun Li*
Abstract 
Background: Previous studies have suggested that people with obesity showed elevated serum levels of leptin as 
well as lipid dysfunction and proprotein convertase subtilisin/kexin type 9 (PCSK9) played an important role in the 
regulation of lipid metabolism recently. The aim of this study was to determine if leptin participated in regulating the 
uptake of low‑density lipoproteins (LDL) in hepatocytes via PCSK9.
Methods: HepG2 cells were treated with human recombinant leptin. The impact of leptin on cellular low density 
lipoprotein receptor (LDLR) and PCSK9 protein levels was determined by Western blot. Dil‑LDL uptake assay was per‑
formed to examine the LDLR function. Specific small interfering RNAs (siRNAs) were used to interfere the expressions 
of target proteins.
Results: The expression of LDLR and LDL uptake could be significantly down‑regulated by leptin treatment while the 
expressions of PCSK9 and hepatocyte nuclear factor 1α (HNF1α) were enhanced in HepG2 cells. Furthermore, inhibi‑
tion of PCSK9 or HNF1α expression by siRNAs rescued the reduction of LDLR expression and LDL uptake by leptin. We 
found that leptin activated the p38 mitogen‑activated protein kinase (p38MAPK) signaling pathway. Moreover, the 
changes of the expressions of HNF1α, PCSK9, LDLR, and LDL uptake induced by leptin could be blocked by p38MAPK 
inhibitor (SB203580). Additionally, leptin attenuated the up‑regulation of LDLR caused by atorvastatin in HepG2 cells.
Conclusions: These findings indicated firstly that leptin reduced LDLR levels in hepatocyte via PCSK9 pathway, sug‑
gesting that PCSK9 might be a alternative target for dyslipidemia in the obesity.
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Background
Obesity is one of the most serious chronic diseases 
worldwide represented by an excess of body fat [1]. 
A number of previous studies indicated that obesity 
increased risk for atherosclerotic cardiovascular disease 
(ASCVD) [2, 3]. Dyslipidemia is the earliest risk factor of 
ASCVD in obesity [4] which includes the elevated serum 
levels of low density lipoprotein cholesterol (LDL-C) [5]. 
It has been demonstrated that elevated LDL-C plays a 
major role in the initiation and development of athero-
sclerosis in patients with overweight and obesity [5–7]. 
Unfortunately, the underlying mechanism responsible for 
elevated LDL-C levels in obesity is not fully understood.
As well established, low density lipoprotein receptors 
(LDLRs) in the surface of hepatocyte membranes func-
tion as critical regulators for circulating LDL-C homeo-
stasis mainly through controlling the rate of liver uptake 
and the clearance of LDL particles [8, 9]. Several physi-
ological factors which could affect the hepatic LDLR 
level are recognized. For instance, resistin, which was 
increased in both circulation and adipose-tissue adipo-
cytes in obesity [10, 11], could reduce LDLR expression 
in human hepatocytes mediated in part by proprotein 
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PCSK9 is a secreted protein which plays a key role in 
regulation of LDL-C level in the circulation by binding 
directly to the hepatic LDLRs and blocking their recy-
cling via promoting its degradation in lysosome [13]. So 
far, there are two best-described trans activator of PCSK9 
gene expression in hepatocytes, sterol response element 
binding proteins (SREBP) [14] and hepatocyte nuclear 
factor 1 alpha (HNF1α) [15].
Besides resistin, leptin is another increased physi-
ological factor in obesity [16] which also comes from 
adipose tissue [17]. The major function of leptin is that 
it decreases food intake and increase energy consump-
tion by acting on specific hypothalamic nuclei CART 
and NPY [18]. Recently, studies in vitro and in vivo have 
suggested that leptin could also be involved in the patho-
physiology of atherosclerosis [19–21]. Furthermore, 
clinical data have shown the plasma leptin level as an 
independent predictor for CVD incident [22]. As such, 
we hypothesized that hyperleptinemia might be another 
potential mechanism linking obesity to ASCVD and lep-
tin could regulate the expression of LDLR in the liver just 
like resistin. Leptin has been reported to stimulate p38 
mitogen-activated protein kinase (p38MAPK) pathway in 
different cell types [23–25] and the p38MAPK pathway 
also participated in the regulation of physiological pro-
cesses associated with atherosclerosis [25, 26]. Therefore, 
we supposed that whether p38MAPK pathway could play 
a role in the regulation of PCSK9 and LDLR by leptin. 
In addition, statins are the major class of drugs to treat-
ment patients with increased serum LDL-C by upregu-
lating the LDLR expression in hepatocytes [12]. It might 
be, therefore, interesting to investigate whether leptin 
could diminish the enhanced LDLR expression induced 
by atorvastatin treatment. These results will help us to 
find out whether leptin could affect the statin-induced 
increase of LDLRs.
In this study, the major goal was to determine if human 
leptin played a role in regulating the uptake of LDL by 
PCSK9 in hepG2 cells for the sake of exploring the poten-
tial links of leptin with PCSK9 in obesity.
Methods
Cell culture and treatment
The human hepatoma cell line HepG2 was purchased from 
Cell Resource Center, IBMS, CAMS/PUMC. HepG2 cells 
were cultured in 10  % fetal bovine serum (FBS) (Gibco)-
containing DMEM (Gibco) supplemented with 1 % NEAA 
(Life technologies), 1 % penicillin- streptomycin at 37  °C, 
5  % (v/v) CO2. HepG2 cells were treated with human 
recombinant leptin protein (R&D Systems, Minneapolis, 
MN, USA) at various doses (0, 5, 25, 50, 100 and 200 ng/
ml) for 24 h or with 50 ng/ml leptin for various times (0, 
6, 12, 24, 48  h). In other experiments, the p38MAPK 
inhibitor-SB203580, was administered at 10  μM, either 
alone or combined with 50 ng/ml leptin for 24 h. Atrovas-
tatin (Sigma, MO) was administered at 10 μM, either alone 
or combined with 50 ng/ml leptin for 24 h.
Western blots
Cultured cells were collected with cell lysis buffer (Beyo-
time, Shanghai, China). Protein samples were separated 
by precast NuPAGE Novex 4–12  % (w/v) Bis–Tris gels 
(Life technologies, Carlsbad, CA, USA) and then trans-
ferred onto nitrocellulose membrane using the iBlotTM 
dry blotting system as described by the manufacturer 
(Invitrogen, Carlsbad, CA, USA). Membranes were 
blocked in TBST buffer (20  mM Tris, pH 7.5, 150  mM 
NaCl, 0.1 % tween 20) containing 5 % milk for 1 h at room 
temperature and incubated with primary antibodies spe-
cific for LDLR (Biovision, Mountain View, CA), PCSK9 
(Cayman Chemicals, MI), HNF1α (Cell Signaling) and 
GAPDH (Abcam) overnight at 4 °C, and then incubated 
with a secondary antibody conjugated with horserad-
ish peroxidase (HRP) for 2 h at room temperature. Blots 
were developed using chemoluminescence (ECL, Thermo 
Fisher Scientific, Waltham, MA, USA) on FluorChem M 
image system.
DiI‑LDL uptake assay
HepG2 cells were changed to serum-free media and incu-
bated with 10 μg/ml DiI-LDL (lifetech) for 24 h at 37 °C 
in the dark. After incubation, the cells were washed with 
PBS and fixed in the presence of a 4 % paraformaldehyde, 
and the nuclei were subsequently stained with Hoechst 
dye. Finally, the cells were examined with fluorescence 
microcopy (DMI-4000B, Leica).
Small interfering ribonucleic acid (siRNA) transfection
PCSK9 and HNF1α Stealth siRNA duplexes are follow-
ings: PCSK9 Stealth siRNA duplexes (Life tech, Carlsbad, 
CA, USA) targeting sequences: 5′-GAC AUC AUU GGU 
GCC UCC AGC GAC U-3′ and 5′-AGU CGC UGG 
AGG CAC CAA UGA UGU C-3′ and HNF1α Stealth 
siRNA duplexes (Life tech, Carlsbad, CA, USA) targeting 
sequences: 5′-UCG AUA CCA CUG GCC UCA ATT-3′ 
and 5′-UUG AGG CCA GUG GUA UCG ATT-3′. The 
negative controls siRNA Duplexes (Life tech, Carlsbad, 
CA, USA) were used as a control. siRNA were transfected 
into HepG2 cells using Lipofectamine TM RNAiMAX 
(Life tech, Carlsbad, CA, USA) according to manufactur-
er’s protocol.
Statistical analysis
Results were presented as mean  ±  SEM at least three 
independent experiments. Significant differences 
between control and treatment groups were assessed by 
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One-way ANOVA with proper posttest or Student two-
tailed t test.
Results
Leptin down‑regulates expression of LDLR 
and up‑regulates expression of PCSK9
To investigate the effect of leptin on the expression of 
LDLR and PCSK9, we treated HepG2 cells with differ-
ent concentrations of leptin (0, 5, 25, 50, 100 and 200 ng/
ml) for 24  h. As a result, the LDLR protein levels were 
decreased and the PCSK9 protein levels were increased 
by leptin stimulation in a dose-dependent manner 
(Fig.  1a, b). Significant changes in LDLR and PCSK9 
protein expression, compared with vehicle-treated cells, 
were observed at 50, 100, 200 ng/ml of leptin treatments. 
Subsequently, we used 50  ng/ml of leptin to stimulate 
HepG2 cells with different times (0, 6, 12, 24, 48 h). The 
impact of leptin on LDLR and PCSK9 appeared in a time-
dependent manner (Fig.  1c, d). The results showed that 
the PCSK9 expression was significantly enhanced by lep-
tin treatment after 12  h and the LDLR expression was 
significantly reduced after 24 h.
PCSK9 inhibition blocks the effect of leptin on LDLR 
expression and LDL uptake
We further investigated whether the down-regulation of 
LDLR by leptin was mediated by PCSK9. HepG2 cells 
were pre-treated with with negative control siRNAs 
(40  nM), which did not target any gene, or the PCSK9 
siRNA for 24 h before the treatment of leptin. Our results 
showed that inhibition of endogenous PCSK9 expression 
using the PCSK9 siRNA (40 nM) abrogated the suppres-
sion of the LDLR expression (Fig. 2a, b) and LDL uptake 
(Fig. 2c) by leptin after 24 h treatment.
HNF1α inhibition blocks the effect of leptin on LDLR 
expression and LDL uptake
HNF1α is an upstream regulator of PCSK9 which can 
bind to the promoter of PCSK9 and directly regulate 
PCSK9 expression [15]. To further confirm that leptin 
promotes PCSK9 expression by the activation of HNF1α, 
we transfected HepG2 cells with HNF1α siRNA for 24 h 
before leptin treatment. The data suggested that inhibi-
tion of endogenous HNF1α expression by the HNF1α 
siRNA (40 nM) could also abrogate the decrease in LDLR 
Fig. 1 The effects of leptin on LDLR and PCSK9 protein levels in HepG2 cells. a Western blot analysis of leptin on LDLR and PCSK9 protein levels in 
HepG2 cells treated with leptin (0, 5, 25, 50, 100 and ng/mL) for 24 h. bThe normalized intensities of LDLR and PCSK9 versus GAPDH are presented 
as the mean ± SD of three independent dose‑dependent experiments. c Western blot analysis of leptin (50 ng/ml) on LDLR and PCSK9 protein 
levels in HepG2 cells treated with leptin for 0, 6, 12, 24, 48 h. d The normalized intensities of LDLR and PCSK9 versus GAPDH are presented as the 
mean ± SD of three independent time‑dependent experiments. *p < 0.05 represent significant differences compared to the vehicle‑treated cells
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expression and increase in PCSK9 expression (Fig. 3a, b) 
as well as the suppression of LDL uptake (Fig. 3c) by lep-
tin after 24 h treatment.
Leptin down‑regulates LDLR and up‑regulates PCSK9 
through p38MAPK pathway
The MAPK signaling cascades have been shown to be 
induced by leptin treatment in different cells [23–25]. 
In this study, we found that phosphorylation of p38 
could be induced by leptin in HepG2 cells in a time-
dependent manner (Fig.  4a, b). To investigate whether 
p38MAPK pathway was involved in the regulation of 
LDLR by leptin, HepG2 cells were co-cultured with the 
p38MAPK specific inhibitor-SB203580 (10  μM) alone 
or combined with leptin. The data indicated that inhibi-
tion of the p38MAPK pathway abolished the decrease in 
LDLR expression and the increase in PCSK9 and HNF1α 
expression (Fig. 4c, d) as well as the suppression of LDL 
uptake (Fig. 4e) by leptin after 24 h treatment.
Leptin inhibits the up‑regulation of LDLR mediated 
by atorvastatin
Additionally, we tested whether leptin inhibited the nor-
mal statin-mediated up-regulation of hepatic LDLR lev-
els. HepG2 cells were treated with atrovastatin (10 μM) 
alone or combined with leptin (50  ng/ml) for 24  h. 
Consistent with previous studies [12], our results showed 
that leptin diminished the increase in hepatic LDLR 
expression induced by atorvastatin treatment (Fig. 5a, b) 
and increase in cellular PCSK9 protein compared with 
atorvastatin treatment alone (Fig. 5c, d).
Discussion
In this study, we, for the first time, demonstrated that 
leptin significantly increased PCSK9 expression and sup-
pressed LDLR in HepG2 cells. The major novel findings 
of the present study were as follows: (1) leptin could sup-
press LDLR level, LDL uptake and elevate PCSK9 expres-
sion; (2) the changes of LDLR, PCSK9 levels and LDL 
uptake were regulated by enhanced expression in HNF1α 
and the elevated activation of p38MAPK pathway; (3) 
leptin could abolish the statin-induced up-regulation 
of hepatic LDLR level. This study revealed a novel role 
of leptin in the regulation of hepatic LDLR and PCSK9 
expression, which might provide additional information 
to understand the mechanism responsible for dyslipi-
demia in obesity.
It is well known that leptin is an adipose tissue-derived 
hormone, which plasma level is positive correlated with 
the body fat mass [16, 17]. The major function of leptin 
is to regulate human body weight and energy homeosta-
sis by the brain [18]. Considering the roles of leptin in 
Fig. 2 Inhibition of PCSK9 expression returned LDLR expression and LDL uptake during leptin treatment in HepG2 cells. a Western blot analysis of 
LDLR and PCSK9 protein levels in HepG2 cells transfected with siPCSK9 (40 nM) and then treated with leptin (50 ng/mL) for 24 h. bThe normalized 
intensities of LDLR and PCSK9 versus GAPDH are presented as the mean ± SD of three independent experiments. c Representative fluorescence 
microscopy images of cell‑associated Dil‑LDL (red), Hoechst‑stained nuclei (blue), and the overlay. *p < 0.05 represent significant differences com‑
pared to the vehicle‑treated cells. #p < 0.05 represent significant differences compared to the leptin‑treated cells
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physiological processes associated with cardiovascular 
disease, such as blood pressure [27], platelet aggrega-
tion [28], arterial thrombosis [29], angiogenesis [30], and 
inflammatory vascular responses [31], it, logically, may 
have a close relationship with the development of CVD 
[32]. Interestingly, study from Kwakernaak et  al. found 
that plasma leptin had a positive association with plasma 
PCSK9 in healthy people [33]. Their results suggested 
that leptin might be involved in the regulation of hepatic 
PCSK9 expression. Therefore, illuminating the relation-
ship of leptin and PCSK9 in vitro is the major goal of this 
study.
In the beginning of this study, we found that leptin 
could cause the decrease of LDLR expression and LDL 
uptake (Additional file 1: Figure S1) in HepG2 cells. Then, 
we sought to illuminate the mechanisms by which lep-
tin regulates the hepatic LDLR levels. Definitely, PCSK9 
have been reported to regulate LDL levels by mediating 
LDLR protein degradation [13]. That is, PCSK9 could 
bind to the extracellular domain of the LDLRs and then 
lead LDLRs to lysosome-mediated degradation instead of 
recycling to the cell surface [13]. Therefore, PCSK9 stood 
a good chance to mediate the regulation of hepatic LDLR 
levels. Consisting with our assumption, the present study 
showed that PCSK9 levels were increased by leptin stim-
ulation. Subsequently, we further investigated the role of 
PCSK9 in the leptin-mediated reduction in LDLR levels. 
In our study, inhibition of PCSK9 gene expression were 
carried out by transfecting PCSK9 siRNA into HepG2 
cells. Negative control siRNAs were used as controls, 
which did not affect expression PCSK9 and LDLR (Addi-
tional file 2: Figure S2). And the relative transfection effi-
ciency was shown by using the positive control–GAPDH 
siRNA and it was great in our experiments (Additional 
file  3: Figure S3). As a result, we found that the sup-
pression of LDLR expression and LDL uptake by leptin 
stimulation could be reversed by the inhibition of PCSK9 
expression. These findings suggested that leptin could 
suppress the LDLR expression by increasing hepatic 
PCSK9 level.
HNF1α is one of the transcriptional regulation factors 
which regulates PCSK9 expression by binding to its pro-
moter [15]. To determine whether HNF1α was involved 
in the regulation of LDLR and PCSK9 by leptin, HNF1α 
siRNAs were used to knockdown its expression. It was 
found that elevation of PCSK9 expression and the reduc-
tion of LDLR expression and function by leptin stimu-
lation could be abolished by the inhibition of HNF1α 
Fig. 3 Inhibition of HNF1α expression returned LDLR and PCSK9 expression and LDL uptake during leptin treatment in HepG2 cells. a Western 
blot analysis of LDLR, PCSK9 and HNF1α protein levels in HepG2 cells transfected with siHNF1α (40 nM) and then treated with leptin (50 ng/mL) for 
24 h. b The normalized intensities of LDLR, PCSK9 and HNF1α versus GAPDH are presented as the mean ± SD of three independent experiments. c 
Representative fluorescence microscopy images of cell‑associated Dil‑LDL (red), Hoechst‑stained nuclei (blue), and the overlay. *p < 0.05 represent 
significant differences compared to the vehicle‑treated cells. #p < 0.05 represent significant differences compared to the leptin‑treated cells
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expression. It is well known that another transcription 
factor, SREBP2 is the most important trans-activator 
of PCSK9 which can also induce LDLR expression [14]. 
Hence, we also examined the SREBP2 expression under 
leptin treatment for 24  h. Interestingly, we found that 
there was no significant change of SREBP2 expression by 
leptin in both mRNA and protein level (Additional file 4: 
Figure S4 and Additional file 5: Figure S5). Although the 
exact reason for this unique phenomenon is unclear, we 
supposed that SREBP2 may not be involved in the regula-
tion of LDLR mediated by PCSK9 under leptin treatment.
Leptin has been reported to signal via various kinases. 
The activity of p38MAPK pathway is also modulated by 
leptin in different cell types. For instance, leptin reduced 
the activity of the Na+/K+ ATPase significantly by 
activating p38MAPK in Caco-2 cells [23]; leptin could 
inhibit glucose intestinal absorption by activation of 
p38MAPK [24]; Besides, leptin also could activate human 
B cells to secrete cytokines via activation of p38MAPK/
ERK1/2 signaling pathways, which may contribute to its 
inflammatory and immunoregulatory properties [34]. 
Furthermore, the p38MAPK pathway has also been 
demonstrated to be participated in the regulation of 
physiological process associated with atherosclerosis. 
Activation of p38MAPK pathway could regulate inter-
leukin-16 -induced migration and invasion of vascular 
smooth muscle cells [26] and be involved in the sup-
pression in oxidized low-density lipoprotein- induced 
endothelial cell apoptosis by paenonl [25]. Therefore, we 
examined whether p38MAPK pathway could be acti-
vated by leptin treatment. Interestingly, we found that 
the phosphorylation of p38 could be increased by leptin 
(Fig. 4a, b). In addition, the inhibition of p38MAPK path-
way by its inhibitor SB203580 could abolish the eleva-
tion in PCSK9 expression and the suppression of LDLR 
expression and LDL uptake by leptin stimulation (Fig. 4c, 
d, e; Additional file 6: Figure S6). On the contrary to our 
results, Pham DD et  al. recently reported that nerve 
growth factor (NGF) could increase LDLR expression 
by stimulation of p38MAPK and activation of caspase-3 
Fig. 4 Leptin modulates LDLR and PCSK9 protein levels and LDL uptake through a p38MAPK‑dependent pathway. a Western blot analysis of phos‑
phorylated‑p38 and total p38 protein levels in HepG2 cells treated with 50 ng/ml leptin for 0, 5, 15, 30, 60, 120 min. b The normalized intensities of 
phosphorylated‑p38 versus total p38 are presented as the mean ± SD of three independent experiments. c Western blot analysis of LDLR, PCSK9 
and HNF1α protein levels in HepG2 cells treated with leptin (50 ng/mL) alone or combined with SB 203580 (10 μM) for 24 h. d The normalized 
intensities of LDLR, PCSK9 and HNF1α versus GAPDH are presented as the mean ± SD of three independent experiments. e Representative fluores‑
cence microscopy images of cell‑associated Dil‑LDL (red), Hoechst‑stained nuclei (blue), and the overlay. *p < 0.05 represent significant differences 
compared to the vehicle‑treated cells. #p < 0.05 represent significant differences compared to the leptin‑treated cells
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and SREBP2 cleavage in hepatocytes [35]. In this study, 
the activation of SREBP2 was mediated by signaling path-
way triggered by ligand-activated p75NTR which were 
induced by p38MAPK and caspase-3. In their study, Cas-
pase-3 activation was caused by p38MAPK following 
NGF stimulations. In our study, leptin did not change the 
levels of SREBP2 proteins including both uncleaved and 
mature form (Additional file 5: Figure S5) but activate the 
p38MAPK. The possible reason is that leptin could sup-
press caspase-3 activity in HepG2 cells [36]. Thereby the 
p75NTR could not be activated and then SREBP2 cleav-
age would not be affected by letpin.
Additionally, statins are the major-class therapy cur-
rently used for patients with increased serum LDL-C by 
upregulating the LDLR expression in hepatocytes [12]. 
Therefore, it might be interesting to investigate whether 
leptin could diminish the enhanced LDLR expression 
induced by atorvastatin treatment. Our results showed 
that leptin could block the increase of LDLR expression 
induced by atorvastatin treatment (Fig. 5). This inhibition 
in the statin-induced LDLR up-regulation by leptin was 
partially contributed by increasing PCSK9 protein level. 
These results suggested that inhibitors for leptin might 
enhance hepatic LDLR expression and reduce plasma 
Fig. 5 The effect of a combination of leptin and atrovastatin in HepG2 cells. a Western blot analysis of LDLR protein levels in HepG2 cells treated 
with leptin (50 ng/mL) alone or combined with atorastatin (10 μM) for 24 h. b The normalized intensity of LDLR versus GAPDH are presented as the 
mean ± SD of three independent experiments. c Western blot analysis of PCSK9 protein levels in HepG2 cells treated with leptin (50 ng/ml) alone or 
combined with atorastatin (10 μM) for 24 h. d The normalized intensity of PCSK9 versus GAPDH are presented as the mean ± SD of three inde‑
pendent experiments. *p < 0.05 represent significant differences compared to the vehicle‑treated cells. #p < 0.05 represent significant differences 
compared to the leptin‑treated cells. &p < 0.05 represent significant differences compared to the atorvastatin‑treated cells
Fig. 6 Summary of pathways by leptin on PCSK9 and LDLR expres‑
sion in HepG2 cells. Stimulation of p38MAPK pathway by leptin 
increased expression of nuclear HNF1α which could bind to PCSK9 
promoter, leading to increase PCSK9 expression in HepG2 cells. The 
increased PCSK9 leaded to elevated LDLR degradation and inhibited 
LDL uptake
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LDL-C level when it was administered combined with 
statins. Further studies are needed to conform our find-
ings and test our hypothesis in the future.
Conclusion
In conclusion, leptin could down-regulate the expression 
and function of LDLR and up-regulate the expression of 
PCSK9 through the p38MAPK- and HNF1α-dependent 
mechanism (Fig.  6). Our findings supported that the reg-
ulation of LDLR and PCSK9 by leptin might be potential 
mechanism linking obesity to ASCVD.
Abbreviations
ASCVD: atherosclerotic cardiovascular disease; HepG2: human hepatocarci‑
noma cell line 2; HNF1α: hepatocyte nuclear factor 1 alpha; LDL: low density 
lipoprotein; LDLR: low density lipoprotein receptor; MAPK: mitogen‑activated 
protein kinase; PCSK9: proprotein convertase subtilisin‑kexin type 9; SREBP: 
sterol response element binding proteins.
Authors’ contributions
DY and LS completed the project, and analyzed the data, and wrote the 
manuscript. LJJ established the study, interpreted the data, and contributed 
to reviewed/edited the manuscript. The other co‑authors for this manuscript 
contributed to collect the data and conduct the experiments. We thank 
Additional files
Additional file 1: Figure S1. Time course of LDL uptake response to 
leptin treatment in HepG2 cells. Representative fluorescence microscopy 
images of cell‑associated Dil‑LDL (red), Hoechst‑stained nuclei (blue), and 
the overlay in HepG2 cells treated with leptin (50 ng/ml) for 0, 6, 12, 24, 
48 h.
Additional file 2: Figure S2. Effect of negative control siRNA on LDLR 
and PCSK9 expression. Real time PCR analysis of LDLR and PCSK9 mRNA 
levels in HepG2 cells transfected with negative control siRNA for 24 h. Con, 
control (vehicle); NC, negative control.
Additional file 3: Figure S3. Knockdown efficiency of GAPDH siRNA in 
HepG2 cells. Real time PCR analysis of GAPDH mRNA levels in HepG2 cells 
transfected with GAPDH siRNA for 24 h. *p < 0.05 represent significant 
differences compared to the vehicle‑treated cells.
Additional file 4: Figure S4. Examination of the effect of leptin on 
PCSK9, LDLR, HNF1α and SREBP2 mRNA Levels in dose‑ or time‑depend‑
ent manner in HepG2 cells. (A) Real time PCR analysis of LDLR, PCSK9, 
HNF1α and SREBP2 mRNA levels in HepG2 cells treated with leptin (0, 
5, 25, 50, 100 and ng/mL) for 24 h. (B) Real time analysis of LDLR, PCSK9, 
HNF1α and SREBP2 mRNA levels in HepG2 cells treated with leptin (50 ng/
ml) for 0, 6, 12, 24, 48 h. *p < 0.05 represent significant differences expres‑
sion compared to the vehicle‑treated cells.
Additional file 5: Figure S5. Effect of leptin on expression of SREBP2. (A) 
Western blot analysis of SREBP2 protein levels in HepG2 cells treated with 
leptin (50 ng/mL) for 24 h. (B) The normalized intensities of uncleaved and 
mature SREBP2 versus GAPDH are presented as the mean ± SD of three 
independent experiments.
Additional file 6: Figure S6. Effect of p38MAPK inhibitor with different 
concentrations on LDLR and PCSK9 expression. (A) Western blot analysis 
of LDLR and PCSK9 protein levels in HepG2 cells treated with leptin 
(50 ng/mL) alone with SB203580 (1 μM or 10 μM) for 24 h. (B) The normal‑
ized intensities of LDLR and PCSK9 versus GAPDH are presented as the 
mean ± SD of three independent experiments. *p < 0.05 represent signifi‑
cant differences compared to the vehicle‑ treated cells. #p < 0.05 represent 
significant differences compared to the leptin‑treated cells.
the staff and participants of this study for their important contributions. All 
authors read and approved the final manuscript.
Acknowledgements
This work was partially supported by the National Natural Science Foundation 
of China (81070171, 81241121), the Specialized Research Fund for the Doctoral 
Program of Higher Education of China (20111106110013), the Capital Special 
Foundation of Clinical Application Research (Z121107001012015), the Capital 
Health Development Fund (2011400302, 2016‑1‑4035), and the Beijing Natural 
Science Foundation (7131014) awarded to Dr. Jian‑Jun Li, MD, PhD.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The relevant raw data will not be shared because the data from cell described 
and presented in the manuscript are completed and clear for testing by 
reviewers.
Received: 16 May 2016   Accepted: 8 September 2016
References
 1. Sainz N, Barrenetxe J, Moreno‑Aliaga MJ, Martinez JA. Leptin resist‑
ance and diet‑induced obesity: central and peripheral actions of leptin. 
Metabolism. 2015;64(1):35–46.
 2. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J 
Clin Endocrinol Metab. 2004;89(6):2595–600.
 3. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. 
Nature. 2006;444(7121):881–7.
 4. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich‑Horvat P, Liu CY, 
Vasan RS, Murabito JM, Meigs JB, Cupples LA, et al. Abdominal visceral 
and subcutaneous adipose tissue compartments: association with 
metabolic risk factors in the Framingham Heart Study. Circulation. 
2007;116(1):39–48.
 5. Superko HR, Gadesam RR. Is it LDL particle size or number that cor‑
relates with risk for cardiovascular disease? Curr Atheroscler Rep. 
2008;10(5):377–85.
 6. Rosenson RS. Low high‑density lipoprotein cholesterol disorders and 
cardiovascular risk: contribution of associated low‑density lipoprotein 
subclass abnormalities. Curr Opin Cardiol. 2005;20(4):313–7.
 7. Rosenson RS. Colesevelam HCl reduces LDL particle number 
and increases LDL size in hypercholesterolemia. Atherosclerosis. 
2006;185(2):327–30.
 8. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH. Apolipoprotein 
B‑100 kinetics in visceral obesity: associations with plasma apolipopro‑
tein C‑III concentration. Metabolism. 2002;51(8):1041–6.
 9. Attie AD, Seidah NG. Dual regulation of the LDL receptor–some clarity 
and new questions. Cell Metab. 2005;1(5):290–2.
 10. Degawa‑Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, 
Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese 
humans. J Clin Endocrinol Metab. 2003;88(11):5452–5.
 11. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz 
Wika J, Goch JH. Resistin increases with obesity and atheroscle‑
rotic risk factors in patients with myocardial infarction. Metabolism. 
2008;57(4):488–93.
 12. Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of 
human resistin in hepatocyte low‑density lipoprotein receptor suppres‑
sion mediated in part by proprotein convertase subtilisin/kexin type 9. J 
Am Coll Cardiol. 2012;59(19):1697–705.
 13. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin 
Lipidol. 2007;18(3):304–9.
 14. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol‑dependent 
regulation of proprotein convertase subtilisin/kexin type 9 expres‑
sion by sterol‑regulatory element binding protein‑2. J Lipid Res. 
2008;49(2):399–409.
Page 9 of 9Du et al. J Transl Med  (2016) 14:276 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 15. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 
1alpha plays a critical role in PCSK9 gene transcription and regulation 
by the natural hypocholesterolemic compound berberine. J Biol Chem. 
2009;284(42):28885–95.
 16. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez‑Reino JJ, Gual‑
illo O. Leptin, from fat to inflammation: old questions and new insights. 
FEBS Lett. 2005;579(2):295–301.
 17. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. 
Positional cloning of the mouse obese gene and its human homologue. 
Nature. 1994;372(6505):425–32.
 18. Arora S. Anubhuti: role of neuropeptides in appetite regulation and 
obesity–a review. Neuropeptides. 2006;40(6):375–401.
 19. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 
2006;189(1):47–60.
 20. Guzik TJ, Mangalat D, Korbut R. Adipocytokines—novel link 
between inflammation and vascular function? J Physiol Pharmacol. 
2006;57(4):505–28.
 21. Dubey L, Hesong Z. Role of leptin in atherogenesis. Exp Clin Cardiol. 
2006;11(4):269–75.
 22. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma 
leptin and prognosis in patients with established coronary atherosclero‑
sis. J Am Coll Cardiol. 2004;44(9):1819–24.
 23. El‑Zein O, Usta J, El Moussawi L, Kreydiyyeh SI. Leptin inhibits the 
Na(+)/K(+) ATPase in Caco‑2 cells via PKC and p38MAPK. Cell Signal. 
2015;27(3):416–23.
 24. El‑Zein O, Kreydiyyeh SI. Leptin inhibits glucose intestinal absorption via 
PKC, p38MAPK, PI3 K and MEK/ERK. PLoS ONE. 2013;8(12):e83360.
 25. Bao MH, Zhang YW, Zhou HH. Paeonol suppresses oxidized low‑
density lipoprotein induced endothelial cell apoptosis via activa‑
tion of LOX‑1/p38MAPK/NF‑kappaB pathway. J Ethnopharmacol. 
2013;146(2):543–51.
 26. Park SL, Hwang B, Lee SY, Kim WT, Choi YH, Chang YC, Kim WJ, Moon SK. 
p21WAF1 Is Required for Interleukin‑16‑Induced Migration and Invasion 
of Vascular Smooth Muscle Cells via the p38MAPK/Sp‑1/MMP‑9 Pathway. 
PLoS ONE. 2015;10(11):e0142153.
 27. Paleczny B, Siennicka A, Zacharski M, Jankowska EA, Ponikowska B, 
Ponikowski P. Increased body fat is associated with potentiation of blood 
pressure response to hypoxia in healthy men: relations with insulin and 
leptin. Clin Auton Res. 2016;26(2):107–16.
 28. Sugiyama C, Ishizawa M, Kajita K, Morita H, Uno Y, Matsubara K, Matsu‑
moto M, Ikeda T, Ishizuka T. Platelet aggregation in obese and diabetic 
subjects: association with leptin level. Platelets. 2007;18(2):128–34.
 29. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin‑
dependent platelet aggregation and arterial thrombosis suggests a 
mechanism for atherothrombotic disease in obesity. J Clin Investig. 
2001;108(10):1533–40.
 30. Tahergorabi Z, Khazaei M. Leptin and its cardiovascular effects: focus on 
angiogenesis. Adv Biomed Res. 2015;4:79.
 31. Abella V, Scotece M, Conde J, Lopez V, Lazzaro V, Pino J, Gomez‑Reino JJ, 
Gualillo O. Adipokines, metabolic syndrome and rheumatic diseases. J 
Immunol Res. 2014;2014:343746.
 32. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly 
A, Wallace AM, Danesh J, Whincup PH. Leptin and coronary heart 
disease: prospective study and systematic review. J Am Coll Cardiol. 
2009;53(2):167–75.
 33. Kwakernaak AJ, Lambert G, Dullaart RP. Relationship of proprotein 
convertase subtilisin‑kexin type 9 levels with resistin in lean and obese 
subjects. Clin Biochem. 2012;45(16–17):1522–4.
 34. Agrawal S, Gollapudi S, Su H, Gupta S. Leptin activates human B cells to 
secrete TNF‑alpha, IL‑6, and IL‑10 via JAK2/STAT3 and p38MAPK/ERK1/2 
signaling pathway. J Clin Immunol. 2011;31(3):472–8.
 35. Pham DD, Do HT, Bruelle C, Kukkonen JP, Eriksson O, Mogollon I, 
Korhonen LT, Arumae U, Lindholm D. p75 neurotrophin receptor signal‑
ing activates sterol regulatory element‑binding protein‑2 in hepatocyte 
cells via p38 mitogen‑activated protein kinase and caspase‑3. J Biol 
Chem. 2016;291(20):10747–58.
 36. Nepal S, Kim MJ, Hong JT, Kim SH, Sohn DH, Lee SH, Song K, Choi DY, Lee 
ES, Park PH. Autophagy induction by leptin contributes to suppression 
of apoptosis in cancer cells and xenograft model: involvement of p53/
FoxO3A axis. Oncotarget. 2015;6(9):7166–81.
